SGO Issues Nov 29, 2018

SGO Issues Nov. 29, 2018

FIGO Oncology Committee updates cervical cancer staging system
New SGO membership categories approved
Coding fellowship available for early career SGO members
SGO endorses document on placenta accreta spectrum
Annual Meeting late-breaking abstract submissions open Dec. 5
Researchers invited to apply for funding through Cancer Moonshot

FIGO Oncology Committee updates cervical cancer staging system

Last week the International Federation of Gynecology and Obstetrics (FIGO) Oncology Committee published the FIGO Cancer Report 2018: Cancer of the cervix uteri in the International Journal of Gynecology & Obstetrics. In an update from the previous FIGO cervical cancer staging, images will be allowed to be incorporated, also surgical resection (pathology) findings will be part of the staging. The updated cervical cancer staging is expected to be adopted internationally by the beginning of 2019; it cannot be adopted in the United States until directed by the American Joint Committee on Cancer (AJCC).

The revised staging was validated in a population-based tumor registry, where possible. According to the report, recent developments in imaging and increased use of minimally invasive surgery have changed the paradigm for management of cervical cancer cases.

Alexander B. Olawaiye, MD, who is a member of the FIGO Oncology Committee along with fellow SGO member Jonathan Berek, MD, MMS, noted that these revisions will have great impact on the treatment of cervical cancer.

“This will allow both developed nations and the low- to middle-income countries to be able to use the same staging,” explained Dr. Olawaiye. “It provides for inclusion of the extent of information that is utilized in staging, and most importantly, staging information will directly correlate/match treatment decisions.”

The FIGO report discusses the management of cervical cancer based on the stage of disease, including attention to palliation and quality of life issues. The authors also recommend primary prevention of cervical cancer with HPV vaccination and secondary prevention of cervical cancer by early detection and treatment of precancerous lesions.

New SGO membership categories approved

Last week a quorum of SGO members voted to pass all proposed amendments to the SGO Bylaws, which has been updated on the SGO website. This includes an amendment to reduce the number of membership categories from nine to four. Next week all SGO members will receive an email from sgo@sgo.org that will confirm their current membership category. The new membership categories are as follows:

  • Full: Includes current Full, Associate, International Affiliate (MD, PhD and MBBS) and Candidate members
  • Associate: Includes current Allied and non-MD International Affiliate members as well as patient advocates
  • Trainee: Includes current Fellows-in-Training (US and international), Resident and Student members
  • Senior: This category has not changed.

After receiving the confirmation email, members who have been assigned to a new category can log in to their SGO account and pay their 2019 dues if they have not yet done so.

A full explanation of the membership changes and reasoning behind them are available on a webinar that was released prior to the Bylaws vote.

Coding fellowship available for early career SGO members

The Society of Gynecologic Oncology (SGO) and the Coding Taskforce have established a two-year Coding Fellowship. The goal of this new program is to nurture and educate physicians on coding and health economics issues, providing the fellow with the tools necessary to advocate on the national level, develop educational tools for SGO membership, and take a leadership role in this vital area in the future. Early Career members (Candidates, Fellows-in-Training) with an interest in coding, billing and practice management are encouraged to apply. Applications must be submitted by Dec. 31, 2018. The first Coding Fellowship recipient will be selected in January 2019 and will receive a complementary registration to attend the SGO Coding Course on March 15, 2019 in Honolulu, HI.

SGO endorses document on placenta accreta spectrum

The Society of Gynecologic Oncology has endorsed the American College of Obstetricians and Gynecologists-Society for Maternal-Fetal Medicine Obstetric Care Consensus Document on “Placenta Accreta Spectrum,” which is now accessible on the ACOG website. 

According to the consensus document, “Placenta accreta is defined as abnormal trophoblast invasion of part or all of the placenta into the myometrium of the uterine wall. Placenta accreta spectrum, formerly known as morbidly adherent placenta, refers to the range of pathologic adherence of the placenta.”

Patients with placenta accreta are at risk of severe and sometimes life-threatening hemorrhage, which often requires blood transfusion. Additionally, women with placenta accreta spectrum are more likely to require hysterectomy at the time of delivery or during the postpartum period and have longer hospital stays.

Because placenta accreta spectrum is considered a high-risk condition with serious associated morbidities, ACOG and the Society for Maternal–Fetal Medicine recommend these patients receive level III (subspecialty) or higher care. This level includes continuously available medical staff with appropriate training and experience in managing complex maternal and obstetric complications, including placenta accreta spectrum as well as consistent access to interdisciplinary staff with expertise in critical care (i.e., gynecologic oncologists or advanced pelvic surgeons, critical care subspecialists, interventional radiologists, hematologists, cardiologists, and neonatologists).

Annual Meeting late-breaking abstract submissions open Dec. 5

The late-breaking abstract submissions for the 2019 SGO Annual Meeting on Women’s Cancer will be open Dec. 5, 2018 through Jan. 7, 2019. The Late-Breaking Abstract session will focus on scientific data that has become available since the original 2019 Annual Meeting abstract submission deadline. Submissions can include preliminary findings if data analysis is still ongoing; however, trials or experiments for which data collection is not yet complete are discouraged. Abstracts should reflect scientific methods and statistical power suitable for a plenary presentation and should not be previously published or presented.

Researchers invited to apply for funding through Cancer Moonshot

The National Cancer Institute (NCI) has recently updated the Cancer Moonshot webpages with descriptive details about all of the initiatives being funded through the Cancer Moonshot. Funding opportunity announcements (FOAs) for cancer researchers for FY 19 are now available and will continue to be published. A list of the most up-to-date FOAs can be found on the Cancer Moonshot page of cancer.gov.